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Abstract: Y-27632 is a well-known inhibitor of the Rho-associated coiled kinase (ROCK) 
and has been shown to significantly improve the culture of a variety of multipotent stem cell 
types. However, the effects of Y-27632 on the expansion of adult human adipose-derived stem 
cell (hADSC) cultures remain to be established. Here, we aimed to characterize the effects of 
Y-27632 on the culture of hADSCs. Adult hADSCs were isolated from subjects submitted to 
elective plastic surgery procedures and cultivated in vitro under optimized conditions. Our results 
show that the continuous supplementation of hADSC cultures with Y-27632 led to decreased 
numbers of cells and decreased global metabolic viability of hADSC cultures when compared 
with control conditions. This effect appeared to be dependent on the continuous presence of 
the drug and was shown to be concentration-dependent and significant for 10 µM and 20 µM 
of Y-27632. Moreover, the Y-27632-induced decrease in hADSC numbers was not linked to a 
block in global cell proliferation, as cell numbers consistently increased from the moment of 
plating until passaging. In addition, Y-27632 was not able to increase the number of hADSCs 
present in culture 24 hours after passaging. Taken together, our results suggest that, in contrast 
to other stem cell types, Y-27632 supplementation is not a suitable strategy to enhance hADSC 
culture expansion.
Keywords: human mesenchymal stem cells, human multipotent stromal cells (hMSCs), ROCK 
inhibitor, MTS assay
Introduction
Stem cells hold the capacity to self-renew and to differentiate into tissue-specific cell 
types. Over the last decades, the identification of different populations of stem cells 
has attracted the interest of the scientific community due to their enormous potential, 
including applications in the field of regenerative medicine and drug discovery.1–3 
Strategies for efficient culture of these stem cells have long been pursued, rendering 
the procedures for stem cell culture less complex over time.4,5 A recently identified 
small molecule that has been proven to be particularly advantageous in stem cell cul-
ture is Y-27632, a selective inhibitor of the Rho-associated coiled kinase (ROCK).6,7 
This compound has been demonstrated to display pleiotropic and wide-range positive 
effects across different cells types, namely human embryonic stem cells (hESCs) and 
human induced pluripotent stem cells (hiPSCs).6,7 Several reports have established that 
treating cultures of adult and human embryonic stem cells with Y-27632 considerably 
increases the post-thaw cell viability, cell attachment, and post-passaging viability, in 
addition to significant improvements in cellular  proliferation.6–10 However, the influ-
ence of Y-27632 in the culture of adult human adipose-derived stem cells (hADSCs) 
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has not yet been thoroughly assessed. The hADSCs constitute 
a population of adult stem cells easily isolated from body 
tissues containing fat.11,12 Similarly to other stem cell types, 
hADSCs retain the capacity to self-renew and to differenti-
ate into diverse cell types, namely adipocytes, osteoblasts, 
chondrocytes, myocytes, cardiomyocytes, and neuron-like 
cells.12–14 Due to their differentiation potential, simplicity to 
isolate, and ability to proliferate in vitro, the scientific com-
munity consider the hADSCs as an increasingly attractive 
source of patient-specific stromal/stem cells.15–17
Here, we set out to investigate if the supplementation of 
hADSC cultures with Y-27632 would significantly improve 
the culture of this population of adult multipotent stromal/stem 
cells. Our results demonstrate a Y-27632-induced decrease 
in hADSC number and global metabolic viability upon con-
tinuous Y-27632 supplementation, in comparison with control 
 conditions. The effect was shown to be  concentration-dependent 
(significant effect for 10 µM and 20 µM of Y-27632) and also 
dependent on the continuous presence of the drug.  Interestingly, 
cell numbers increased from the moment of plating until 
passaging, so that the Y-27632-induced decrease in hADSC 
numbers was not linked to a block in global cell proliferation. 
In addition, Y-27632 could not increase the number of hADSCs 
present in culture 24 hours after passaging. Together, our results 
suggest that Y-27632 supplementation alone is not an appropri-
ate strategy to significantly improve the culture conditions of 
adult hADSCs.
Materials and methods
Adult human adipose-derived  
stem cells isolation
Adult hADSCs were kindly provided by Jeffrey M Gimble 
(Pennington Biomedical Research Center, Baton Rouge, LA, 
USA). Cells were isolated according to a protocol previously 
described by Dubois et al.18 Briefly, liposuction aspirates from 
subcutaneous adipose tissue were obtained from patients sub-
mitted to elective plastic surgery procedures. All donors gave 
their written informed consent. Tissues were then digested in 
a 0.1% collagenase type I solution (Worthington Biochemical 
Corporation, Lakewood, NJ, USA) pre-warmed to 37°C for 
60 minutes. Afterward, the digested tissue was centrifuged for 
5 minutes at 300–500 g at room temperature. The supernatant, 
containing mature adipocytes, was aspirated. The pellet 
was identified as the stromal vascular fraction (SVF). The 
SVF was resuspended and plated in T225 flasks in Stromal 
Medium (Dulbecco’s Modified Eagle’s Medium [DMEM]/
Ham’s F-12, 10% fetal bovine serum [FBS; Hyclone, Logan, 
UT, USA], 100 U penicillin/100 µg streptomycin/0.25 µg 
Fungizone®) at a density of 0.156 mL of tissue digest/cm2 of 
surface area for expansion and culture. After reaching conflu-
ency, cells were passaged and kept in stromal medium.
Adult human adipose-derived stem cells 
culture and survival/proliferation studies
In this work, we used hADSCs previously cultured and 
cryopreserved between p5 and p10. All cell cultures were 
maintained in a humidified incubator at 37°C and 5% CO
2
. 
After quickly thawing the vials in a 37°C water bath, cells 
were resuspended in culture medium containing Minimum 
 Essential Medium α (α-MEM; Thermo Fisher Scientific, 
Waltham, MA, USA) supplemented with 10% FBS (Thermo 
Fisher Scientific), 100 units/mL penicillin (Thermo Fisher 
Scientific), and 100 µg/mL streptomycin (Thermo Fisher 
Scientific ). Cells were then spun at 1,200 g for 5 minutes. The 
supernatant was gently aspirated and cells resuspended in the 
same culture medium and plated in a T75 flask and allowed to 
expand. Media was changed every 3–4 days. Upon confluency, 
cells were trypsinized and passaged to new T75 flasks or plated 
in 6-, 12-, or 24-well plates (Nunc; Thermo Fisher  Scientific) 
for the survival/proliferation studies. These  survival/prolifera-
tion studies were carried out using cells plated at two initial 
seeding densities (1,000 and 5,000 cells/cm2). Y-27632 was 
added to the wells within the first 60 minutes after cell plating. 
Throughout the study, medium was changed in all conditions 
at selected time points. Cells were fixed at the desired time 
points (24 hours and 5 days post-plating). In each study, 2–3 
replicate wells were used per studied condition.
Y-27632
The putative ROCK inhibitor Y-7632 was purchased from 
Abcam (ab120129; Cambridge, UK) and dissolved in deion-
ized filtered water to yield a 10 mM stock solution. Aliquots 
were prepared and stored at –20°C.
Cell viability assessment
Cell metabolic viability was assessed by performing 
MTS assays. The MTS 3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium 
test. The MTS test  (Promega Corporation, Fitchburg, WI, 
USA) is a cell viability assay based on the bioreduction of 
the substrate (MTS) to a brown formazan product. After the 
desired cell culture period, the medium was aspirated and 
cells replenished with a new serum-free medium containing 
MTS in a 5:1 ratio and incubated at 37°C with 5% humidified 
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CO
2
. Three hours post-incubation, 150 µL of each sample 
were transferred to 96-well plates (n=3 or 4) and optical 
density (OD) at 490 nm was determined using a Model 680 
Microplate Reader (Bio-Rad Laboratories Inc., Hercules, 
CA, USA).
Cell proliferation
The cellular proliferation of hADSCs was determined by a 
colorimetric assay based on 5-bromo-2′-deoxyuridine (BrdU) 
incorporation (Hoffman-La Roche Ltd, Basel, Switzerland). 
Cells were incubated with BrdU over 48 hours. After the 
BrdU incubation period, an enzyme-linked immunosorbent 
assay (ELISA) test was performed according to the manu-
facturers recommended protocol. In the end, the OD was 
determined at 370 nm with a reference filter at 492 nm using 
an Infinite 200 PRO NanoQuant Reader (Tecan Group Ltd, 
Männedorf, Switzerland).
Immunocytochemistry
Adult hADSCs cultures were pre-fixed by adding one 
volume of cold 4% paraformaldehyde diluted in phosphate-
buffered saline 1× (PBS 1×/4% PFA) for 2 minutes at room 
temperature. Then, cells were fixed with PBS 1×/4% PFA 
for 30 minutes at 4°C. After fixation, cells were washed with 
PBS 1× three times and then incubated in 0.1 µg/mL of red 
phalloidin (Sigma-Aldrich Co, St Louis, MO, USA) diluted 
in PBS 1× for 1 hour at room temperature. In the end, cells 
were again washed with PBS 1× and finally incubated in a 
solution containing 1 µg/mL 4′,6-diamidino-2-phenylindole 
(DAPI; Thermo Fisher Scientific) for 20 minutes. Cells were 
washed again with PBS 1× and then imaged.
Image acquisition and quantitative  
image analysis
Image acquisition was performed using an IX-81  fluorescence 
microscope (Olympus Corporation, Tokyo, Japan). Seven rep-
resentative fields of each well were selected in a blinded and 
systematic procedure using 10× magnification.  Automated 
quantitative determination of DAPI-positive nuclei was 
performed using the Cell Scoring module of Metamorph NX 
software (Molecular Devices LLC,  Sunnyvale, CA, USA). 
Positive cells were selectively identified when having clear 
signal intensity above local background. Intensity thresholds 
were set blinded to sample identity and in a given experi-
ment, identical parameters were used in all images analyzed. 
The parameters were minimally adjusted across the different 
independent experiments.
Statistical analysis
All quantitative data were analyzed using GraphPad Prism 
for Windows (v5.00; GraphPad Software, San Diego, CA, 
USA). For each set of data, each condition was compared 
using one-way analysis of variance (ANOVA) statistical 
evaluation followed by Tukey’s honestly significant differ-
ence (HSD) post hoc test. In cases involving only one time 
point and a two-group comparison, P-value was determined 
using Student’s t-tests. Differences were considered to be 
significant when P,0.05.
Results
The expansion of hADSCs is not 
enhanced in the presence of Y-27632
Several reports in the last decade have demonstrated that 
Y-27632 efficiently improves the culture conditions of a 
myriad of human stem cell types, including hESCs,  hiPSCs, 
human mesenchymal stem cells (hMSCs) and human neu-
ronal progenitor cells (hNPCs).6,7,9,10,19–23 However, the influ-
ence of Y-27632 in the culture of adult hADSCs remains to 
be firmly established. Here, we first aimed to assess if the 
presence of Y-27632 in the culture medium could improve 
the overall expansion of hADSCs. Human ADSCs p5 and 
p10 were grown in T75 flasks until confluency (Figure 1A). 
Afterward, cells were trypsinized and the resultant cell sus-
pension recovered to be replated in 12-well plates. The pilot 
experiments performed showed that hADSC cultures seeded 
initially at the standard 5,000 cells/cm2 seeding density 
would reach confluency after 5 days of continuous culture 
(control hADSC growth  condition;  Figure 1B). Thus, all 
subsequent expansion experiments were conducted until day 
5 after hADSC  plating. To evaluate the effect of Y-27632 in 
hADSCs, these adult stem cells were grown under continu-
ous standard 10 µM Y-27632 supplementation for 5 days 
(Y-27632 D0–D5); Y-27632 treatment for the first 24 hours 
followed by culture in regular growth conditions for the next 
4 days (Y-27632 D0–D1); or growth in control conditions 
(control; Figure 1A). Two initial cell-seeding densities (1,000 
and 5,000 cells/cm2) were used (Figure 1A and B).  During 
the 5-day period, a continuous increase in the number of 
hADSCs was registered across the three different medium 
supplementation conditions. At day 5, the cell cultures were 
fixed with PFA and stained for quantification of the number 
of hADSCs present in the culture. Using 10× magnification, 
seven representative fields of each well were then imaged in 
a blinded and systematic manner (Figure 2A). Automated 
quantitative image analysis of hADSCs present in the wells 
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Figure 1 The continuous presence of 10 µM Y-27632 did not lead to enhanced hADSC expansion.
Notes: (A) Diagram of the protocol used to study the effect of Y-27632 in hADSCs cultured over 5 days. Two initial seeding densities (1×103 and 5×103 cells/cm2) were 
used for these studies. Cells were grown in control growth medium for 5 days (Control); Y-27632 treatment for the first 24 hours and then growth in control medium for 
the next 4 days (Y-27632 D0–D1); or continuously cultivated in the presence of 10 µM Y-27632 for 5 days (Y-27632 D0–D5). (B) Representative images of hADSC cultures 
after 5 days of continuous culture. None of the treatments could halt cellular proliferation, and therefore, cell numbers increased significantly from day 1. Uninterrupted 
supplementation of hADSCs with 10 µM Y-27632 led to a lower cell number at day 5 comparative to control conditions. A few cells grown under the continuous influence of 
Y-27632 evidenced a neuronal-like morphology after 5 days (yellow arrows), but failed to demonstrate robust expression of putative neuronal markers. Scale bar = 80 µm.
Abbreviation: hADSCs, human adipose-derived stem cells.
was then performed using the Cell Scoring module of the 
Metamorph NX software (Figure 2B). After 5 days of cell 
culture, we registered similar numbers of hADSCs in the 
control and Y-27632 D0–D1 wells (Figures 1B, 2C, and 2D). 
On the other hand, Y-27632 D0–D5 wells had  significantly 
decreased numbers of hADSCs when compared to the 
control and Y-27632 D0–D1 wells (Figures 1B, 2C, and 2D). 
The analysis of the global cell metabolic viability using the 
MTS test revealed significantly decreased OD in hADSCs 
grown continuously in the presence of Y-27632 (Y-27632 
D0–D5; Figure 2E and F). These results were observed for 
both seeding densities tested (Figure 2C–F). Remarkably, the 
number of hADSCs present in culture was also diminished 
even if the Y-27632 treatment was continuously applied over 
4 days from day 1 to day 5 (data not shown). Interestingly, 
at day 5, we observed that a few cells treated with Y-27632 
over 5 days exhibited neuron-like morphology (Figure 1B; 
Y-27632 D0–D5). However, those cells failed to express 
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Figure 2 Cell number and cellular viability of hADSC cultures at day 5.
Notes: (A) Image acquisition for cell number quantification was performed in a blinded procedure through acquisition of images at 10× magnification in seven systematic 
regions (red dots) in each well studied. (B) Sample image of DAPI-stained hADSCs and corresponding overlay for automated quantitative determination of DAPI-positive 
nuclei using the Cell Scoring module of Metamorph NX software. Scale bar =110 µm. (C) Continuous Y-27632 supplementation attenuated the expansion of hADSCs seeded 
initially at 1×103 cells/cm2 and (D) 5×103 cells/cm2. Values shown as mean ± SEM, n=5 (***P,0.001, *P,0.05, ns = not significant). (E) The sustained treatment with 10 µM 
Y-27632 led to decreased cellular viability in hADSCs seeded initially at 1×103 cells/cm2, and (F) 5×103 cells/cm2 when compared to control conditions. Values shown as mean ± 
SEM, n=5 (***P,0.001, **P,0.01, ns = not significant).
Abbreviations: DAPI, 4′,6-diamidino-2-phenylindole; hADSCs, human adipose-derived stem cells; MTS, 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfonyl)-2H-tetrazolium; OD, optical density; SEM, standard error of the mean.
 putative neuronal markers, namely the  microtubule-associated 
protein 2 (MAP-2) as assessed by immunocytochemistry 
performed under optimized  conditions in three independent 
experiments. Taken together, these results highlight that the 
continuous presence of Y-27632 in hADSC cultures could 
lead to decreased numbers of cells in culture when compared 
to control conditions, in contrast to what has been widely 
demonstrated in other stem cell types.
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The effect of Y-27632 in hADSC cultures  
is concentration-dependent
To further confirm that the continuous presence of Y-27632 
in culture does not enhance the expansion of hADSCs, 
we aimed to determine whether the effect of Y-27632 in 
hADSCs was concentration-dependent. Thus, we next per-
formed studies involving serial concentrations of Y-27632 
starting at 20 µM. For this set of experiments, hADSCs were 
seeded initially at 5,000 cells/cm2 in 24-well plates. Three 
replicate wells were used for each concentration tested. At 
the end of the optimized 5-day culture period, we observed 
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Figure 3 The effect of Y-27632 on the culture of hADSCs is concentration-dependent.
Notes: (A) Over 5 days, hADSCs were cultured under optimized conditions (without Y-27632) and in the presence of increasing concentrations of Y-27632. Cell numbers 
were significantly decreased when hADSCs were cultured with continuous 10 µM or 20 µM Y-27632 supplementation. Values shown as mean ± SEM, n=5 (***P,0.001). (B) 
hADSCs had significantly increased average nuclear area and (C) decreased global cell metabolic viability when cultured in the presence of 10 µM or 20 µM Y-27632. Values 
shown as mean ± SEM, n=5 (***P,0.001, *P,0.05).
Abbreviations: hADSCs, human adipose-derived stem cells; MTS, 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfonyl)-2H-tetrazolium; OD, optical 
density; SEM, standard error of the mean.
a robust concentration-dependent decrease in hADSC num-
bers in cultures treated continuously with Y-27632 (Figure 
3A). The calculated half maximal effective concentration 
(EC
50
) for the continuous Y-27632 treatment was deter-
mined to be ≈7.97 µM. The decrease in cell numbers was 
statistically significant for the concentrations 10 µM and 
20 µM  (Figure 3A). These concentrations of Y-27632 were 
associated with significant increases in the average nuclear 
area of hADSCs (Figure 3B) and a significant decrease 
in the global cellular metabolic viability (Figure 3C). 
Together, our results not only demonstrate a robust Y-27632 
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concentration-dependent decrease in hADSC numbers, but 
also show for the first time that the standard 10 µM concen-
tration of Y-27632, commonly associated with pro-expansion 
effects in most stem cell types, does not enhance the culture 
of hADSCs.
Effect of Y-27632 in the viability  
and continued culture of hADSCs
The initial experiments which demonstrated that continuous 
Y-27632 supplementation is not beneficial for hADSC culture 
were performed using cells in passage .6. It is possible that at 
this later passage, cells have lost their multipotency and have 
become nonresponsive to the standard 10 µM concentration of 
Y-27632. To rule out this possibility and to elucidate further 
the effect of Y-27632 in the hADSC cultures, we conducted 
a new set of experiments using hADSCs in earlier  passages 
(,p4). hADSCs were again grown in T75 flasks until conflu-
ency (Figure 4A). Afterwards, cells were trypsinized and the 
resultant cell suspension recovered to be replated at 5,000 
cells/cm2 in 6-well plates. Cells were then allowed to expand 
over 5 days in the continuous presence or absence of the 
standard 10 µM Y-27632. After 5 days, cells were trypsinized 
and counted with the help of a  hematocytometer. Our data 
showed decreased numbers of cells in the wells treated 
with Y-27632 for 5 days (Figure 4B), which shows that the 
decrease in hADSC number upon Y-27632 treatment is also 
observed in earlier passages of hADSCs.
Numerous reports demonstrate that Y-27632 treatment 
is associated with enhanced survival of recently passaged 
cells.7,8,24,25 To determine if Y-27632 is also able to enhance 
the survival of hADSCs after cell passaging, cells grown for 
5 days in the presence or absence of Y-27632 were replated 
and cultured for the next 24 hours with or without Y-27632 
(Figure 4A and C). After 24 hours, we registered similar 
numbers of hADSCs in the untreated and Y-27632-treated 
wells (Figure 4C; ns = not significant). This observation was 
present in cells either grown with or without Y-27632 in the 
previous 5 days. Together, these results show that Y-27632 
is not able to significantly increase the survival of recently 
passaged hADSCs.
We next aimed to assess the effect of prolonged 
Y-27632 supplementation on the continuous proliferation 
and viability of hADSCs. Those hADSCs grown initially 
over 5 days in the presence or absence of Y-27632 were 
passaged and allowed to re-expand for an additional 5 days 
(Figure 4A and D). After passaging, each initial group of 
cells was subsequently submitted to treatment with or without 
Y-27632 (Figure 4A and D). Therefore, hADSCs were grown 
under four different medium conditions (Figure 4A): 10 days 
of growth in control conditions (C/C); 5 days of growth 
in control conditions plus 5 days of continuous Y-27632 
supplementation (C/Y); 5 days of growth with Y-27632 fol-
lowed by growth in control conditions (Y/C); and 10 days 
of growth with Y-27632 treatment (Y/Y). We observed a 
continuous increase in the number of hADSCs in culture in 
both the first and the second period of 5 days of cell culture 
across the different growth conditions, which shows that 
Y-27632 treatment does not block the proliferation of hAD-
SCs  (Figure 4C vs 4D). After 10 days of culture, the wells 
submitted to a continuous treatment with Y-27632 during 
the second growth period had the lowest number of hADSCs 
(C/Y and Y/Y; Figure 4D). Contrarily, cells grown under 
control conditions in both periods had the greatest number 
of hADSCs in culture (C/C; Figure 4D).  Interestingly, in the 
wells submitted to an initial 5-day treatment with Y-27632 and 
then a second period of growth in control conditions (Y/C), 
the number of hADSCs present in culture was similar to 
growth in control conditions for the 10 days (C/C; Figure 4D). 
In line with this, the global metabolic viability of hADSCs 
was decreased in the wells treated with Y-27632 for the last 
5 days of cell growth (C/Y and Y/Y; Figure 4E). Yet, we did 
not register significant differences in the global levels of 
cell proliferation among the four growth conditions studied 
(Figure 4F). Together, this data reveals a long-term decrease 
in the number of hADSCs in the presence of Y-27632 when 
compared to control conditions. Our results also suggest that 
the removal of the drug from the growth medium allows cul-
tures to re-expand up to the levels similar to that of the control 
growth condition, implying that the effects of Y-27632 on 
hADSC cultures are not irreversible, but seem to depend on 
the continuous presence of the drug.
The previous experiments were performed under a 
paradigm of continuous Y-27632 supplementation. To further 
confirm that the decrease in the number of hADSCs pertained 
by Y-27632 depends on continuous drug supplementation, we 
performed the same experiments under a paradigm of transient 
Y-27632 treatment during the 24 hours prior to cell passag-
ing (Figure 5A). We observed that the 24 hours of treatment 
did not have a significant impact on the total number of cells 
retrieved from the wells after 5 days of hADSC expansion, 
resulting in similar total cell yields when compared to the con-
trol conditions (Figure 5A and 5B). In line with previous data, 
24 hours after hADSC passaging, we registered similar num-
bers of hADSCs in the untreated and Y-27632-treated wells 
(Figure 5C), further confirming that Y-27632 does not seem to 
significantly enhance the survival of hADSCs. The hADSCs 
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Figure 4 Prolonged Y-27632 supplementation is not associated with improvements in the expansion and survival of hADSCs.
Notes: (A) Diagram of the protocol used to study the effect of prolonged Y-27632 supplementation in early passage hADSC cultures. hADSCs were grown initially over 5 
days in the presence or absence of Y-27632. Afterwards, cells were passaged and allowed to grow for an additional 5 days. The hADSCs from the two initial groups were 
each grown subsequently with or without Y-27632. (B) At the end of the initial 5 days of culture, continuous Y-27632 treatment led to systematically decreased numbers of 
hADSCs, even at early passages of hADSCs. Values shown as mean ± SEM, n=5 (*P,0.05). (C) Twenty-four hours after passaging, Y-27632 supplementation did not promote 
enhanced survival of hADSCs. This result was observed whether previous 5-day treatment with Y-27632 was present or absent. Values shown as mean ± SEM, n=4 (ns = 
not significant). (D) After 10 days of cell culture, hADSC numbers were significantly decreased in wells grown continuously with Y-27632 for the previous 5 days. An initial 
exposure to Y-27632 for 5 days followed by growth in control conditions did not preclude hADSCs to re-expand up to levels similar to the control conditions. Values shown 
as mean ± SEM, n=5 (**P,0.01, *P,0.05). (E) The continuous presence of Y-27632 was associated with decreased global cellular metabolic viability of hADSCs after 10 days 
of culture. Values shown as mean ± SEM, n=5 (*P,0.05, ns = not significant). (F) Global hADSC proliferation remained apparently unaffected by the presence of Y-27632, 
which is in line with the observed increase in cell numbers in both 5-day periods of cell culture studied. Values shown as mean ± SEM, n=3.
Abbreviations: BrdU, 5-bromo-2′-deoxyuridine; hADSCs, human adipose-derived stem cells; MTS, 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfonyl)-
2H-tetrazolium; OD, optical density; SEM, standard error of the mean; C, control; Y, Y-27632.
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Figure 5 Y-27632 exposure over 24 hours prior to cell passaging was not associated with improvements in the expansion and survival of hADSCs.
Notes: (A) Diagram of the protocol used to study the effect of Y-27632 supplementation 24 hours before passaging in hADSC cultures. (B) At the end of the initial 5 days of 
culture, transient 24-hour exposure of hADSCs to Y-27632 treatment did not alter the number of cells retrieved upon passaging at day 5. Values shown as mean ± SEM, n=5 
(ns = not significant). (C) Twenty-four hours after passaging, Y-27632 supplementation was not linked to enhancements in the survival of hADSCs. This result was observed 
whether treatment with Y-27632 in the preceding 24 hours was present or absent. Values shown as mean ± SEM, n=4 (ns = not significant). (D) After 10 days of cell culture, 
hADSC numbers were significantly decreased in wells grown continuously with Y-27632 for the previous 5 days. An initial exposure to Y-27632 for 24 hours followed by 
growth in control conditions did not preclude hADSCs to expand up to levels similar to the control conditions. Values shown as mean ± SEM, n=5 (**P,0.01, *P,0.05). 
(E) Continuous Y-27632 supplementation was associated with decreased global cellular metabolic viability of hADSCs after 10 days of culture. Values shown as mean ± SEM, 
n=5 (**P,0.01, * P,0.05, ns = not significant). (F) Global hADSC proliferation levels in the presence of Y-27632 were similar to control conditions, which is in line with the 
observed increase in cell numbers in both 5-day periods of cell cultures studied for control and Y-27632-treated wells. Values shown as mean ± SEM, n=3.
Abbreviations: BrdU, 5-bromo-2′-deoxyuridine; hADSCs, human adipose-derived stem cells; MTS, 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfonyl)-
2H-tetrazolium; OD, optical density; SEM, standard error of the mean; C, control; Y, Y-27632.
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exposed to Y-27632 over the 24 hours before passaging were 
also replated and allowed to cultivate for an additional 5 days 
with and without Y-27632 (Figure 5A and 5D). As a result, the 
cells were again studied in four different medium conditions 
(Figure 5A): 10 days of culture in control conditions (C/C); 5 
days of growth in control conditions plus 5 days of continuous 
Y-27632 supplementation (C/Y); 4 days of growth in control 
conditions followed by a 24-hour exposure to Y-27632; and 
then either growth in control conditions (Y/C) or 5-day growth 
submitted to Y-27632 (Y/Y). Here, we also observed a contin-
uous increase in the number of hADSCs in culture in both the 
first and the second period of 5 days of cell culture across the 
different growth conditions (Figure 5C vs 5D). After 10 days 
of culture, the wells submitted to Y-27632 treatment during 
the second growth period had the lowest number of hADSCs 
(Figure 5D) and cells grown under control conditions for the 
entire 10-day period had the greatest number of hADSCs in 
culture (Figure 5D). Interestingly, in the wells where hADSCs 
were submitted to an initial 24 hours of Y-27632 treatment and 
then a second period of growth in control conditions (Y/C), the 
number of hADSCs present in culture was similar to growth 
in control conditions for the 10 days (C/C; Figure 5D). The 
global metabolic viability of hADSCs was decreased in the 
wells continuously treated with Y-27632 for the last 5 days 
of cell growth (Figure 5E). Interestingly, we did not register 
significant differences in the levels of cell proliferation among 
the four medium combinations tested (Figure 5F). This data 
further confirms that the continued decrease in the number of 
hADSCs in the presence of Y-27632 depends on the constant 
presence of the drug.
Taken together, the data reported in the present study 
demonstrate for the first time that continuous supplementa-
tion of hADSC cultures with Y-27632, even at the standard 
10 µM concentration, does not constitute a beneficial strategy 
to improve the culture of hADSCs.
Discussion
The continuous addition of Y-27632 to stem cell cultures 
has been linked to considerable improvements in the expan-
sion of some stem cell populations, specifically hPSCs and 
hNPCs.6,23,26–28 We showed here that growing hADSC cultures 
in the presence of Y-27632 did not add benefits in terms of 
cell numbers and cell viability; moreover, the continuous 
presence of Y-27632 was shown to be detrimental for the 
expansion of this population of stem cells given that cell num-
bers and cell metabolic viability were significantly decreased 
in the different paradigms studied when compared to control 
conditions. However, the decrease in the number of hADSCs 
upon continuous treatment with Y-27632 was not linked to a 
block in cell proliferation, as cell numbers increased during 5 
days and global BrdU levels were similar in wells treated with 
or without Y-27632. In addition, the removal of the Y-27632 
compound from the medium allowed cells previously exposed 
to Y-27632 treatment (either 24 hours or 5 days continuously) 
to expand up to the levels of the control condition, which 
implies that the effects of Y-27632 on hADSC cultures 
reported here are not irreversible, but seem to depend on the 
continuous presence of the drug.29 Therefore, it is plausible 
that Y-27632 is lengthening the progression of the dividing 
hADSCs through the cell cycle, which could explain overall 
lower hADSC numbers in comparison to control conditions, 
despite similar global levels of BrdU in the 48-hour pulse per-
formed. Our results are in line with previous studies showing 
that the expansion of CD34+ hematopoietic progenitor cells 
is impaired in the presence of Y-27632.30,31 Both hADSCs 
and CD34+ hematopoietic progenitor cells are adult stem 
cells of mesodermal origin and Y-27632 could be decreasing 
their expansion rates by using a common mechanism. The 
present study also showed that the application of Y-27632 
to recently passaged hADSC cultures did not significantly 
increase the number of hADSCs 24 hours after passaging 
when compared to control conditions. This result is in contrast 
with studies involving other stem cells types, namely hPSCs, 
in which this compound is known to significantly increase 
cell survival of those stem cells upon dissociation due to 
its well-known antiapoptotic effects.27,28 It is possible that 
the proapoptotic mechanisms activated in hPSCs upon dis-
sociation differ from the possible proapoptotic mechanisms 
present in hADSCs in the first 24 hours after cell passaging. 
On the other hand, the molecular inhibition pertained by this 
compound in hADSCs (mesenchymal lineage) might lead 
to a diverse cellular phenotype from what has been widely 
described for hPSCs. Future studies are needed to thoroughly 
address the cellular mechanisms responsible for the diverse 
responses of different stem cell types to Y-27632.
The great majority of studies in the literature that dem-
onstrate the beneficial effects of Y-27632 for cell prolif-
eration and survival have been obtained using a standard 
10 µM concentration of Y-27632. Here, we studied different 
concentrations of Y-27632 and showed that in wells grown 
continuously under 10 µM or 20 µM of Y-27632, there are 
significantly decreased numbers of hADSCs. Previous in vitro 
studies involving Y-27632 have established that this compound 
at 10 µM concentration, besides ROCK, can in addition 
strongly inhibit other kinases, namely PRK2, mitogen- and 
stress-activated protein kinase-1 (MSK1), leucine-rich repeat 
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protein kinase-2 (LRRK2), and MNK1.32,33 This might 
explain the observed decrease in the number of viable cells 
at day 5 upon continuous Y-27632 supplementation, since 
the sustained inhibition of several protein kinases might be 
detrimental to cellular homeostasis in the long run.
A recent report in the literature has proposed that  hADSCs 
treated with Y-27632 develop morphological changes resem-
bling neuron-like cells.34 Here, the continuous presence of 
Y-27632 led to the appearance of hADSCs with similar 
neuron-like shapes. We could demonstrate that these cells fail 
to express putative neuronal markers, namely MAP-2. Yet, it 
remains to be confirmed that Y-27632 alters the lineage com-
mitment potential of hADSCs. Eventually, these morphological 
changes add another layer of evidence to highlight the negative 
value of adding Y-27632 to hADSC cultures, if the purpose is 
to culture this type of adult stem cells more efficiently.
Conclusion
The present work shows that Y-27632 supplementation not 
only does not increase the plating efficiency of hADSCs, but 
also fails to enhance the expansion of this type of human 
adult stem cells. In contrast to other stem cell types, Y-27632 
supplementation does not seem to constitute a successful 
strategy to improve hADSC cultures.
Acknowledgments
We thank Jeffrey M Gimble (Center for Stem Cell Research 
and Regenerative Medicine, Tulane University and LaCell 
LLC, New Orleans, LA, USA) for kindly isolating, character-
izing, and sharing the cellular lines of hADSCs used in the 
present study and for critical input on the manuscript. We also 
would very much like to thank Laurent Roybon (Stem Cell 
Laboratory for CNS Disease Modeling, Department of Experi-
mental Medical Science, Lund University, Lund, Sweden) for 
the utilization of Metamorph NX software for automated cell 
quantification. We are grateful to Miguel Carvalho, Ana Pires, 
Eduardo Gomes, Fábio Teixeira and Nuno Silva for technical 
assistance. This work was supported by the Portuguese Foun-
dation for Science and Technology (predoctoral fellowship to 
NJL [SFRH/BD/33421/2008]; FCT Investigator Program to 
AJS) and the Luso-American Development Foundation.
Author contributions
NJL: collection of data, conception and design, data analysis 
and interpretation, manuscript writing; SCS: collection of 
data, data analysis and interpretation, manuscript writing; 
AJS: conception and design, data analysis and interpretation, 
manuscript writing; NS: conception and design, data analysis 
and interpretation, manuscript writing. All authors read and 
approved the final manuscript.
Disclosure
The authors report no conflicts of interest in this work.
References
 1. Evans M. Discovering pluripotency: 30 years of mouse embryonic stem 
cells. Nature reviews. Nat Rev Mol Cell Biol. 2011;12(10):680–686.
 2. Gokhale PJ, Andrews PW. Human embryonic stem cells: 10 years on. 
Lab Invest. 2009;89(3):259–262.
 3. Kørbling M, Estrov Z. Adult stem cells for tissue repair – a new thera-
peutic concept? N Engl J Med. 2003;349(6):570–582.
 4. Valamehr B, Tsutsui H, Ho CM, Wu H. Developing def ined 
culture systems for human pluripotent stem cells. Regen Med. 
2011;6(5):623–634.
 5. Villa-Diaz LG, Ross AM, Lahann J, Krebsbach PH. Concise review: 
the evolution of human pluripotent stem cell culture: from feeder cells 
to synthetic coatings. Stem Cells. 2013;31(1):1–7.
 6. Kurosawa H. Application of Rho-associated protein kinase 
(ROCK) inhibitor to human pluripotent stem cells. J Biosci Bioeng. 
2012;114(6):577–581.
 7. Watanabe K, Ueno M, Kamiya D, et al. A ROCK inhibitor permits 
survival of dissociated human embryonic stem cells. Nat Biotechnol. 
2007;25(6):681–686.
 8. Pakzad M, Totonchi M, Taei A, Seif inejad A, Hassani SN, 
 Baharvand H. Presence of a ROCK inhibitor in extracellular matrix 
supports more undifferentiated growth of feeder-free human embryonic 
and induced pluripotent stem cells upon passaging. Stem Cell Rev. 
2010;6(1):96–107.
 9. Gauthaman K, Fong CY, Bongso A. Effect of ROCK inhibitor Y-27632 
on normal and variant human embryonic stem cells (hESCs) in vitro: 
its benefits in hESC expansion. Stem Cell Rev. 2010;6(1):86–95.
 10. Li X, Meng G, Krawetz R, Liu S, Rancourt DE. The ROCK 
inhibitor Y-27632 enhances the survival rate of human embryonic 
stem cells following cryopreservation. Stem Cells Dev. 2008; 
17(6):1079–1085.
 11. Gimble J, Guilak F. Adipose-derived adult stem cells:  isolation, character-
ization, and differentiation potential. Cytotherapy. 2003;5(5):362–369.
 12. Gimble JM, Katz AJ, Bunnell BA. Adipose-derived stem cells for 
regenerative medicine. Circ Res. 2007;100(9):1249–1260.
 13. Bunnell BA, Estes BT, Guilak F, Gimble JM. Differentiation of adipose 
stem cells. Methods Mol Biol. 2008;456:155–171.
 14. Lindroos B, Suuronen R, Miettinen S. The potential of adipose stem 
cells in regenerative medicine. Stem Cell Rev. 2011;7(2):269–291.
 15. Aguena M, Fanganiello RD, Tissiani LA, et al. Optimization of 
parameters for a more efficient use of adipose-derived stem cells in 
regenerative medicine therapies. Stem Cells Int. 2012;2012:303610.
 16. Mizuno H, Tobita M, Uysal AC. Concise review: adipose-derived 
stem cells as a novel tool for future regenerative medicine. Stem Cells. 
2012;30(5):804–810.
 17. Salgado AJ, Reis RL, Sousa NJ, Gimble JM. Adipose tissue derived 
stem cells secretome: soluble factors and their roles in regenerative 
medicine. Curr Stem Cell Res Ther. 2010;5(2):103–110.
 18. Dubois SG, Floyd EZ, Zvonic S, et al. Isolation of human adipose-
derived stem cells from biopsies and liposuction specimens. Methods 
Mol Biol. 2008;449:69–79.
 19. Nakamura K, Yoshimura A, Kaneko T, Sato K, Hara Y. ROCK inhibitor 
Y-27632 maintains the proliferation of confluent human mesenchymal 
stem cells. J Periodontal Res. 2014;49(3):363–370.
 20. Claassen DA, Desler MM, Rizzino A. ROCK inhibition enhances 
the recovery and growth of cryopreserved human embryonic stem 
cells and human induced pluripotent stem cells. Mol Reprod Dev. 
2009;76(8):722–732.
Stem Cells and Cloning: Advances and Applications
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/stem-cells-and-cloning-advances-and-applications-journal
Stem Cells and Cloning: Advances and Applications is an international, 
peer-reviewed, open access journal. Areas of interest in stem cell 
research include: Embryonic stem cells; Adult stem cells; Blastocysts; 
Cordblood stem cells; Stem cell transformation and culture; Therapeutic 
cloning; Umbilical cord blood and bone marrow cells; Laboratory, 
animal and human therapeutic studies; Philosophical and ethical issues 
related to stem cell research. This journal is indexed on CAS. The 
manuscript management system is completely online and includes a 
quick and fair peer-review system. Visit http://www.dovepress.com/
testimonials.php to read real quotes from published authors.
Stem Cells and Cloning: Advances and Applications 2015:8submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Dovepress
26
Lamas et al
 21. Heng BC. Effect of Rho-associated kinase (ROCK) inhibitor Y-27632 
on the post-thaw viability of cryopreserved human bone marrow-derived 
mesenchymal stem cells. Tissue Cell. 2009;41(5):376–380.
 22. Li X, Krawetz R, Liu S, Meng G, Rancourt DE. ROCK inhibitor 
improves survival of cryopreserved serum/feeder-free single human 
embryonic stem cells. Hum Reprod. 2009;24(3):580–589.
 23. Rungsiwiwut R, Manolertthewan C, Numchaisrika P, et al. The ROCK 
inhibitor Y-26732 enhances the survival and proliferation of human 
embryonic stem cell-derived neural progenitor cells upon dissociation. 
Cells Tissues Organs. 2013;198(2):127–138.
 24. Zhang L, Valdez JM, Zhang B, Wei L, Chang J, Xin L. ROCK inhibitor 
Y-27632 suppresses dissociation-induced apoptosis of murine prostate 
stem/progenitor cells and increases their cloning efficiency. PLoS One. 
2011;6(3):e18271.
 25. Ramasamy TS, Yu JS, Selden C, Hodgson H, Cui W. Application of 
three-dimensional culture conditions to human embryonic stem cell-
derived definitive endoderm cells enhances hepatocyte differentiation 
and functionality. Tissue Eng Part A. 2013;19(3–4):360–367.
 26. Ohgushi M, Sasai Y. Lonely death dance of human pluripotent stem 
cells: ROCKing between metastable cell states. Trends Cell Biol. 
2011;21(5):274–282.
 27. Ohgushi M, Matsumura M, Eiraku M, et al. Molecular pathway and 
cell state responsible for dissociation-induced apoptosis in human 
pluripotent stem cells. Cell Stem Cell. 2010;7(2):225–239.
 28. Chen G, Hou Z, Gulbranson DR, Thomson JA. Actin-myosin con-
tractility is responsible for the reduced viability of dissociated human 
embryonic stem cells. Cell Stem Cell. 2010;7(2):240–248.
 29. Chapman S, McDermott DH, Shen K, Jang MK, McBride AA. The 
effect of Rho kinase inhibition on long-term keratinocyte proliferation 
is rapid and conditional. Stem Cell Res Ther. 2014;5(2):60.
 30. Bueno C, Montes R, Menendez P. The ROCK inhibitor Y-27632 nega-
tively affects the expansion/survival of both fresh and cryopreserved 
cord blood-derived CD34+ hematopoietic progenitor cells: Y-27632 
negatively affects the expansion/survival of CD34+HSPCs. Stem Cell 
Rev. 2010;6(2):215–223.
 31. Burthem J, Rees-Unwin K, Mottram R, et al. The rho-kinase inhibi-
tors Y-27632 and fasudil act synergistically with imatinib to inhibit 
the expansion of ex vivo CD34(+) CML progenitor cells. Leukemia. 
2007;21(8):1708–1714.
 32. Davies SP, Reddy H, Caivano M, Cohen P. Specificity and mecha-
nism of action of some commonly used protein kinase inhibitors. 
Biochem J. 2000;351(Pt 1):95–105.
 33. Nichols RJ, Dzamko N, Hutti JE, et al. Substrate specificity and inhibi-
tors of LRRK2, a protein kinase mutated in Parkinson’s disease. Biochem 
J. 2009;424(1):47–60.
 34. Xue ZW, Shang XM, Xu H, et al. Rho-associated coiled kinase 
inhibitor Y-27632 promotes neuronal-like differentiation of adult 
human adipose tissue-derived stem cells. Chin Med J (Engl). 
2012;125(18):3332–3335.
